What Can We Learn from COVID-19 Drug Development and Access for Non-Pandemic Diseases? A Chinese Perspective.

Zhang, Hui; Guo, Zhiping; Shen, Lijun; Yang, Yongguang; Zhang, Zhenxiang; Wang, Yuming

Zhang, Hui; Guo, Zhiping; Shen, Lijun; Yang, Yongguang; Zhang, Zhenxiang; Wang, Yuming.

Zhang H; Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University.
Guo Z; Zhengzhou University.
Shen L; Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University.
Yang Y; Fuwai Central China Cardiovascular Hospital.
Zhang Z; Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University.
Wang Y; Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University.

Am J Bioeth ; 21(12): 42-45, 2021 12.

Article in English | MEDLINE | ID: covidwho-1528090

Subject(s)

COVID-19; China; Drug Development; Health Services Accessibility; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: Am J Bioeth Journal subject: Ethics Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google